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In Brief
Szeg } o et al. identify HSP10 as a modulator of alpha-synuclein-induced mitochondrial impairment in striatal synaptosomes. Age-associated increase in the cytosolic and decrease in mitochondrial levels of HSP10 results in a reduction in the levels of SOD2 and of synaptosomal ATP production on demand. HSP10 overexpression delays alpha-synuclein pathology both in vitro and in vivo.
INTRODUCTION
A major pathological hallmark of Parkinson's disease (PD) and other synucleinopathies is the presence of intraneuronal inclu-sions known as Lewy bodies (LBs) and Lewy neurites (LNs). These inclusions are composed mainly of a-synuclein (aSyn) but are known to also contain mitochondrial proteins (Leverenz et al., 2007; Xia et al., 2008) . Moreover, mitochondrial dysfunction has been implicated in the pathogenesis of PD: complex I deficiency was detected in the substantia nigra (SN) (Schapira et al., 1989) , muscle (Blin et al., 1994) , and platelets (Parker et al., 1989) of PD patients, and mutations in several mitochondria-related genes are associated with familial forms of the disease (Corti et al., 2011; Bose and Beal, 2016; Chang et al., 2017) .
aSyn is considered primarily a cytoplasmic protein, but recent evidence suggests that it may also accumulate in mitochondria (Hu et al., 2019; Wang et al., 2019) and associate with mitochondria-associated endoplasmic reticulum (ER) (Chinta et al., 2010; Guardia-Laguarta et al., 2014) . Whether aSyn plays a physiological role in mitochondria is unclear, but increased aSyn levels inhibit cellular respiration (Chinta et al., 2010; Wang et al., 2019; Zambon et al., 2019) , induce mitophagy and mitochondrial fragmentation (Nakamura et al., 2008 (Nakamura et al., , 2011 , affect mitochondrial Ca 2+ homeostasis (Calì et al., 2012) and protein import (Di Maio et al., 2016) and turnover (Hu et al., 2019) , and reduce mitochondrial membrane potential (Banerjee et al., 2010) , suggesting a pathological role that culminates with mitochondrial dysfunction.
Here, we hypothesized that aSyn-dependent mitochondrial dysfunction might initiate in the synapse, because aSyn is likely to start accumulating in the cytoplasm of the presynaptic terminals (Kramer and Schulz-Schaeffer, 2007) and then progress toward the perinuclear region to induce additional cellular pathologies. First, we screened for aSyn-interacting proteins in nerve terminals (striatal synaptosomes) and identified the 10 kDa heat shock protein (HSP10) as an aSyn interactor and mediator of aSyn-associated mitochondrial dysfunction. Importantly, we obtained detailed insight into the mechanisms through which the accumulation of aSyn, a predominantly cytosolic protein, can induce cellular pathologies by affecting mitochondrial functions. We found that accumulation of aSyn in middle-age transgenic animals sequesters HSP10 in the cytosol, reducing its mitochondrial function in the HSP10/HSP60 complex, which resulted in a reduction in the levels of the client protein superoxide dismutase 2 (SOD2). This led to increased mitochondrial oxidative stress and impaired respiration. Interestingly, improving mitochondrial health by restoring the levels of HSP10 delayed aSyn-induced mitochondrial pathology both in vitro and in vivo. Our findings provide novel mechanistic information on the molecular underpinnings of PD and might help in designing novel therapeutic strategies for PD and other synucleinopathies.
RESULTS
The HSP10 Chaperonin Interacts with aSyn in Striatal Synaptosomes aSyn interacts with several synaptic and mitochondrial proteins (Betzer et al., 2015) and affects both synaptic and mitochondrial functions (Guardia-Laguarta et al., 2014; Calo et al., 2016; Di Maio et al., 2016; Faustini et al., 2017; Hu et al., 2019; Wang et al., 2019; Zambon et al., 2019) . However, the effects of aSyn in striatal synaptosomal mitochondria have not been addressed in detail. To assess the molecular underpinnings of aSyn-mediated toxicity in striatal mitochondria, we performed a proteomics-based unbiased screen for aSyn-interacting partners in nerve terminals (synaptosomal component). We identified aSyn-interacting proteins in preparations from transgenic overexpressing human aSyn (wild-type aSyn [WTaSyn]) or from control mice. In total, we identified 67 proteins (Table S1 ). Of those 67 proteins, we selected the HSP10 for further validation, because it forms, together with HSP60, a major folding complex in mitochondria (David et al., 2013) . HSP10 is a major hub protein for cellular interactions (Rizzolo et al., 2018) and regulates several mitochondrial functions, including respiration, membrane potential, and reactive oxygen species (ROS) removal. Therefore, even subtle changes in its concentration may affect the functionality of several proteins and cellular functions. The regulation of HSP10 levels in neurological diseases is not well understood (Hickey et al., 2000; Bross et al., 2007; Kim and Lee, 2007; Bie et al., 2016; Bross and Fernandez-Guerra, 2016; Fan et al., 2017) , and to our knowledge, this has not been investigated in the context of synucleinopathies. To assess whether the level of HSP10 is altered in human brain tissue, we fractionated putamen samples of patients with PD and controls (Figures 1A and 1B) . We found that levels of synaptosomal HSP10 were reduced in samples from patients. In contrast, the levels of HSP60, the protein partner of HSP10 in the mitochondrial folding complex, and the levels of soluble aSyn were not altered. In parallel, the levels of synaptosomal SOD2 were also reduced in PD brains. Although we found no change in the levels of soluble aSyn in striatal synaptosomes, we detected the colocalization of HSP10 and phospho-aSyn (paSyn) in post-mortem tissue (putamen) from PD patients and from patients with de-mentia with LBs (DLBs) but not from control brains ( Figure 1C ; Figure S1 ). We could also co-immunoprecipitate HSP10 and aSyn from striatal synaptosomal samples of WT or aSyn transgenic mice ( Figure 1D ). In addition, we found colocalization of HSP10 and aSyn in primary cortical neurons using a proximity ligation assay (PLA; Figure S2 ). To further validate these results, we used surface plasmon resonance (SPR), a technique that enables estimation of the kinetics and binding constants for protein-protein interactions. We confirmed a high-affinity interaction between HSP10 and monomeric, oligomeric, and pre-formed fibrils (PFFs) of aSyn ( Figure 1E ). Interestingly, we found that monomeric and PFFs of aSyn showed similar binding affinities to HSP10 (monomeric: K D = 2.9 mM, k a = 11.92 M À1 s À1 , k d = 3.46 3 10 À5 s À1 ; PFF: K D = 5.27 mM, k a = 11.00 M À1 s À1 , k d = 5.95 3 10 À5 s À1 ) and that oligomeric aSyn had lower affinity to HSP10 (K D = 27.2 mM, k a = 6.8 M À1 s À1 , k d = 1.85 3 10 À4 s À1 ).
The Subcellular Distribution of HSP10 Is Altered in Middle-Age aSyn Transgenic Mice Next, we assessed the levels of HSP10 in striatal synaptosomal mitochondria of aSyn transgenic and control mice ( Figure 2 ). The levels of mitochondrial HSP10 were reduced in both young and middle-age transgenic animals (Figures 2A-2D ), but the levels of total striatal HSP10 were not altered either by genotype or by age ( Figure 2F ). In parallel, the levels of cytosolic HSP10 were increased in both young and middle-age A30PaSyn mice ( Figure 2E ). To unequivocally confirm the identity and integrity of HSP10, we used a parallel gel electrophoresis approach and subjected the gel band corresponding to immunodetected HSP10 to in-gel protein digestion followed by mass spectrometric protein identification . Both mitochondrial and cytosolic HSP10 were identified with the same high sequence coverage (Figures 2G and 2H) .
Because the HSP60/HSP10 complex is an important player in mitochondrial folding, we next asked whether there were functional consequences of the age-associated decreased levels of mitochondrial HSP10. To better distinguish between synaptic and general effects, we fractionated striatal samples, prepared from young or middle-age animals, into synaptosome and total mitochondrial fractions ( Figure S3A ). We found reduced spare respiratory capacity (SRC; a measure of mitochondrial function) in synaptosomes prepared from young aSyn transgenic animals ( Figure S3B ) but not in total mitochondria fractions ( Figure S3C ). In middle-age transgenic mice, both synaptosomal ( Figure S3D ) and total mitochondrial SRC ( Figure S3E ) decreased compared with control animals. In addition, we found that mitochondrial ROS handling ( Figure S3F ), mitochondrial membrane potential ( Figure S3G ), and the opening of the mitochondrial permeability transition pore (mPTP; Figure S3H ) were also compromised selectively in the striatal synaptic compartment but not in total mitochondrial fractions ( Figures S3I and S3J ).
HSP10 Improves Mitochondrial Functions in Primary Neuronal Cultures
Because we found reduced levels of mitochondrial HSP10 in the brains of both PD patients and aSyn transgenic animals, we hypothesized that this might be associated with the functional deficits observed in mitochondria. Therefore, we next tested whether increasing the levels of HSP10 would ameliorate aSynassociated mitochondrial dysfunction. First, we generated an in vitro model of synucleinopathies in primary striatal cultures, in which moderate overexpression of aSyn resulted in mild mitochondrial dysfunction. Neurons were infected with lentivirus encoding human WTaSyn, A30PaSyn, or GFP, as control protein. To test whether expression of HSP10 would modify aSyn-induced mitochondrial dysfunction, neuronal cultures were infected with lentivirus encoding for Flag-tagged HSP10 (HSP10-Flag) or GFP. Therefore, we generated six experimental groups: GFP+GFP, GFP+HSP10, WTaSyn+GFP, WTaSyn+HSP-10, A30PaSyn+GFP, and A30PaSyn+HSP10.
We found that expression of human aSyn resulted in a $30% increase in the total levels (both rodent and human) of aSyn compared with control cells (GFP+GFP versus WTaSyn+GFP or A30PaSyn+GFP) ( Figures 3A and 3B ; Figure S4A ). Expression of human aSyn reduced the levels of endogenous HSP10 just moderately ( Figure S4B ) but did not affect the levels of HSP60 ( Figure 3B ; Figure S4C ). Expression of human aSyn increased ER stress (elevated levels of growth arrest and DNA damage 153 [GADD153]) ( Figures S4D and S4E ) and reduced the levels of the mitochondrial serine protease high temperature-regulated A2 (HtrA2) ( Figure S4F ) and SOD2 ( Figures 3B and 3C ). mPTPs were more open in cells expressing A30PaSyn ( Figure S4G ). Interestingly, although basal mitochondrial ROS levels were not increased ( Figure S4H ), removal of mitochondrial ROS was less efficient in H 2 O 2 -treated cells ( Figure 3D ) when human aSyn was expressed. In contrast, basal cytoplasmic ROS levels were higher ( Figure S4I ), but H 2 O 2 -induced ROS elimination was identical in GFP-expressing and in human aSyn-expressing cells ( Figure S4J ). Expression of both WTaSyn and A30PaSyn significantly reduced the SRC of striatal neurons, with a greater decrease in the A30PaSyn-expressing cultures (Figures 3E and 3F) .
Expression of HSP10-Flag resulted in a $2-fold increase in the total levels of HSP10 protein (GFP+HSP10, WTaSyn+HSP10, and A30PaSyn+HSP10; Figure 3B ; Figure S4B ). In WTaSynexpressing cells, overexpression of HSP10 resulted in increased SOD2 levels ( Figures 3B and 3C ), and consequently, removal of mitochondrial ROS upon H 2 O 2 treatment was improved ( Figure 3D ). In addition, the mitochondrial HtrA2 levels (Figures S4D and S4F) and SRC ( Figures 3E and 3F) were both normalized. In contrast, although basal cytoplasmic ROS decreased in cells co-expressing WTaSyn and HSP10 ( Figure S4I ), ER stress levels were not changed (Figures S4D and S4E) .
Overexpression of HSP10 in A30PaSyn-infected cells improved the elimination of mitochondrial ROS after oxidative (C) Immunoblot images show mitochondrial (left) and cytoplasmic (right) HSP10 levels in young and old, control (WT), and A30PaSyn transgenic mice. Mitochondrial levels of HSP10 decreased in both young and middle-age WTaSyn (upper left) and A30PySyn (lower left) mice. In contrast, cytoplasmic levels of HSP10 increased with age in transgenic mice (in WTaSyn mice, it was detectable just in middle-age animals; upper right panel). In A30PaSyn mice, the levels of cytoplasmic HSP10 were increased already in younger animals (lower right) and were further increased with age. (D) Quantification of the mitochondrial HSP10 levels of WTaSyn and control (upper panel) and A30PaSyn and its control (lower panel) shows reduced protein signal in both young and old transgenic animals. (E) Quantification of cytoplasmic HSP10 signal shows increased level of HSP10 in aged WTaSyn mice, and in both young and old A30PaSyn mice, compared with control. (F) Representative immunoblots showing the total level of HSP10 in WT and aSyn transgenic mice. No differences in the total levels of HSP10 were found. (G) Colloidal Coomassie staining (upper image), HSP10 immunoblot (middle image), and pseudo-colored overlay (lower image) of the same protein lysates. The overlay was used to determine the region to be excised from the Coomassie gel for subsequent MS protein identification (areas indicated by rectangles). Mito, mitochondria sample; Cyto, cytoplasmic sample; conc Cyto, concentrated cytoplasmic sample. (H) In the amino acid sequence of HSP10 (UniProtKB/Swiss-Prot Q64433), peptides identified by MS are underlined (orange, peptides identified from the mitochondrial fraction; dark green, peptides identified from the cytoplasmic fraction, major lower band; light green, peptides identified from the cytoplasmic fraction, minor upper band). Data are presented as mean ± SD. *p < 0.05. 
HSP10 Reduces aSyn Pathology
The aggregation of aSyn is enhanced in oxidative environments (Hashimoto et al., 1999; Fernandes et al., 2014; Scudamore and Ciossek, 2018) . Because increasing the levels of HSP10 improved mitochondrial ROS handling and decreased basal cytoplasmic ROS levels, we next tested whether HSP10 overexpression modulated aSyn aggregation. We compared the levels of aSyn phosphorylation on S129 (paSyn, used as a readout of aSyn pathology) in neurons expressing WTaSyn or A30PaSyn together with either HSP10 or GFP (see the six groups above) (Oueslati, 2016) . After 2 weeks in culture, paSyn was found mostly in puncta along the neurites (Figures 4A and 4B) and colocalized almost completely with synapsin (Figures 4F and 4G) in all cultures expressing human aSyn. Two weeks later, most neurons expressing human aSyn + GFP displayed paSyn in the soma, and the colocalization of paSyn and synapsin was reduced. Interestingly, HSP10 delayed the re-localization of pa-Syn-positive puncta from the neurites toward the soma, and the colocalization with synapsin remained relatively high even after 4 weeks in culture ( Figures 4B and 4G) .
To further confirm the modulation of aSyn aggregation by HSP10, we assessed the solubility of aSyn in Triton X-100 in the older cultures ( Figures 3C-3E ). We found that the ratio of insoluble to soluble aSyn decreased in primary cells expressing WTaSyn+HSP10 compared with cells expressing WTaSyn+GFP. However, HSP10 expression had no effect in A30PaSyn-expressing cells ( Figures 4C-4E ).
Next, we assessed the conversion of monomeric aSyn into fibrils in vitro, using the real-time quaking-induced conversion (RT-QuIC) assay (Candelise et al., 2019; van Rumund et al., 2019) . Briefly, WTaSyn or A30PaSyn monomers were incubated in the presence or absence of HSP10, and the aggregation was monitored by measuring thioflavin T fluorescence. Alternatively, WTaSyn or A30PaSyn monomers were seeded with PFFs of WTaSyn in the presence of HSP10. Only freshly thawed aSyn monomers were used, and the quality of the preparations was assessed using immunoblot ( Figure 5A ). WTaSyn monomers aggregated even without PFF seeding ( Figure 5B ) and HSP10 increased aggregation. Interestingly, in the presence of PFF seeds, HSP10 decreased aSyn aggregation ( Figure 5C ). In contrast, A30PaSyn monomers formed almost no thioflavin T-positive species without PFF seeding, irrespective of the presence of HSP10 ( Figure 5B ). Although the presence of PFF seeds increased A30PaSyn aggregation, HSP10 had no effect ( Figure 5C ).
aSyn Affects HSP10/HSP60 Folding Activity Because we found increased levels of cytoplasmic HSP10 in middle-age transgenic mice, we hypothesized that cytosolic aSyn might bind to and, therefore, sequester HSP10 in the cytoplasm, reducing the amount of protein that would normally localize in mitochondria. As a corollary of this hypothesis, this should result in reduced folding capacity of the HSP60/HSP10 complex. To test this, we used two distinct approaches. One mimicked a situation in which different aSyn species (monomers, oligomers, and PFFs) would interact with Hsp10 in the cytosol ( Figure 5D , pre-incubation with HSP10). The other mimicked a situation in which the different aSyn species would interact with the HSP60/HSP10 complex in mitochondria ( Figure 5D , incubation with HSP10 and HSP60). Interestingly, while aSyn monomers increased the folding activity when pre-incubated with HSP10 (before adding HSP60), incubation of aSyn together with HSP10 and HSP60 did not change complex activity. Oligomeric aSyn species reduced the folding activity only when added together with HSP10 and HSP60. In contrast, aSyn PFFs preincubated with HSP10 significantly reduced the folding activity of the complex but had no effect when incubated together with HSP10 and HSP60 ( Figure 5D ). These findings suggest conformation-specific interactions between aSyn and HSP10, consistent with the SPR data, and suggest that aggregated aSyn in the cytosol impairs the activity of the HSP10/HSP60 complex.
HSP10 Improves Mitochondrial Function In Vivo
Next, to determine whether we could rescue aSyn-associated pathologies in vivo, we injected lentiviruses encoding either HSP10 or GFP in the SN of WT or aSyn transgenic mice. HSP10 and GFP were detected both in synaptosomes prepared from the striatum and in dopaminergic neurons of the SN (Figures 6A and 6D) . One month after viral injection, neither the number of tyrosine hydroxylase (TH)-positive (dopaminergic) (legend continued on next page) neurons nor the total number of neurons (Nissl) changed compared with control mice (Figures S5A and S5B ). We found no alterations in the levels of synaptophysin or PSD95 in striatal synaptosomes ( Figure 6B ). ER stress (GADD153) was increased, and SOD1 and SOD2 levels were decreased in transgenic mice ( Figure 6C ). Expression of HSP10 did not change the levels of SOD1. In contrast, it decreased the levels of GADD153 in WTaSyn transgenic animals ( Figure 6B ). The levels of synaptosomal SOD2, a protein folded by the HSP60/HSP10 complex, was restored to control levels upon overexpression of HSP10 ( Figure 6B) . Interestingly, increased striatal HSP10 also reduced aSyn aggregation in synaptosomes of WTaSyn transgenic mice, as assessed using Triton X-100 solubility ( Figure 6C ).
Next, we hypothesized that the restoration of SOD2 levels in HSP10-injected animals might reduce mitochondrial ROS levels and/or improve ROS handling. Although basal mitochondrial ROS levels were not altered by HSP10 overexpression, the handling of ROS upon H 2 O 2 stress improved in HSP10-injected WTaSyn transgenic mice and was identical to that observed in control animals ( Figures 6E and S5F-S5H ).
Because the folding and import of several mitochondrial proteins, including components of the respiratory chain, are mediated by the HSP60/HSP10 complex (Tang et al., 2016) , we next tested whether HSP10 would also restore mitochondrial SRC. We found that HSP10 significantly increased SRC in striatal synaptosomes prepared from WTaSyn animals but not from A30PaSyn mice (Figures 6G and 6H ).
DISCUSSION
Consistent with the occurrence of functional synaptic alterations in early, preclinical stages of synucleinopathies, we discovered that in the nigrostriatal system, aSyn-induced synaptic mitochondrial pathology starts prior to the total mitochondrial pathology. We report that aSyn interacts with HSP10 in the striatal synaptic compartment and that this interaction results in the sequestration of HSP10 in the cytosol in conditions of increased aSyn load, leading to the impairment of several mitochondrial functions. We hypothesized that this happens because when HSP10 is sequestered in the cytosol, the normal folding of client proteins of the mitochondrial HSP10/HSP60 complex is compromised. By increasing the levels of HSP10, we improved aSyn-associated mitochondrial dysfunction and delayed aSyn pathology.
When levels of aSyn are increased, because of age-associated changes in its turnover or because of the effect of PTMs Vicente Miranda et al., 2017) , aSyn may gain toxic properties and associate with mitochondria.
Consistently, overexpression of aSyn or treatment of cells with aSyn oligomers or fibrils also induces severe mitochondrial deficits, including fragmentation (Nakamura et al., 2011) , mitophagy (Chinta et al., 2010) , and impaired mitochondrial protein import (Di Maio et al., 2016) . However, the precise effect of aSyn on mitochondrial function is still controversial. Although some studies show no effect of aSyn in dopaminergic nerve terminals (Pathak et al., 2017) , others have reported protection even against the mitochondrial toxin MPP + (Dauer et al., 2002; Fountaine and Wade-Martins, 2007) .
To gain insight into the initial effects of aSyn in nerve terminals, we searched for aSyn interactors in striatal synaptosomes. Among several other candidates, we identified HSP10 as a novel aSyn-interacting protein and asked whether manipulating the levels of this small heat shock protein could reverse aSyn-associated cellular pathologies. HSP10 is encoded by a nuclear gene (HSPE1, 2q33.1), arranged head to head with the gene encoding HSP60 and controlled by the same bi-directional promoter (Hansen et al., 2003) . In mitochondria, HSP10 assembles into either an asymmetric (one HSP10 heptameric ring) or a symmetric (two rings) complex with an HSP60 14-mer. Interestingly, the levels of HSP10 limit the formation of the symmetric complexes, and the asymmetric complex has reduced folding capacity (Nisemblat et al., 2015) . Because the HSP10/HSP60 complex is one of the most important players in mitochondrial quality control (Horwich et al., 2007; Campos et al., 2016) , reduced function of the complex results in embryonic lethality (Christensen et al., 2010) , and a heterozygous mutation in the HSPE1 gene associates with severe, early-onset neurological disorder in humans (Bie et al., 2016) . Although the mutant protein is functional, its resistance to proteases is substantially reduced, resulting in an almost 2-fold reduction in the HSP10/HSP60 ratio. Because decreased HSP10 concentration forces the formation of the asymmetric, less efficient, folding complex, the levels of client proteins, such as SOD2, are reduced to just 20% of the normal levels, and mitochondrial ROS levels are increased (Azem et al., 1995) . Our finding that, in parallel with reduced mitochondrial HSP10 levels in striatal synaptosomes, both mitochondrial ROS removal and SOD2 level are decreased, suggests that HSP10 may play a central role in aSyn-associated mitochondrial dysfunction in synucleinopathies. Although in our model, the levels of other mitochondrial proteins (e.g., TOM20, HSP60, frataxin; data not shown) were not altered, we cannot rule out that aSyn alters mitochondrial protein import through another mechanism. Our results also suggest that the A30P mutation in aSyn may potentiate the interaction between aSyn and HSP10, leading to an earlier decrease in mitochondrial HSP10 levels and mitochondrial dysfunction.
(D) Representative microscopy images of the SN of wild-type (WT BDF or WT Bl6) and transgenic (WTaSyn or A30PaSyn) mice after injection of GFP as control or HSP10-Flag encoding virus. Scale bar: 200 mm (103) or 20 mm (603). Thirty micrometer coronal section containing the SN where the virus injection was visible was stained with anti-tyrosine hydroxylase antibody (TH; red) to detect dopaminergic neurons, anti-GFP or anti-Flag antibody (green) to detect the expression of exogenous protein, and DAPI (blue). (E) Mitochondrial ROS handling in striatal synaptosomes improved in WTaSyn mice upon HSP10 overexpression (n = 4). (F) The FCCP-induced depolarization in striatal synaptosomes of WTaSyn mice, but not in A30PaSyn mice, was reduced upon HSP10 overexpression (n = 4). (G) Change in SRC in striatal synaptosomes normalized to preparations from WT control animals (n = 5). (H) Mitochondrial respiration measured by relative OCR levels in striatal synaptosomes, under basal conditions (measurement at 5 and 10 min) or following the addition of oligomycin (15 min), the uncoupler FCCP (20 min), or rotenone and antimycin (25 min). Data are presented as mean ± SD. *p < 0.05.
Given that HSP10 is synthetized in the cytosol, and that aSyn is also primarily a cytosolic protein, we hypothesized that the main site for the interaction between the two proteins would be the cytosol. We predicted that increased levels of aSyn would bind more HSP10 and, consequently, reduce its mitochondrial levels and activity, thereby leading to the impairment of mitochondrial quality control and respiration at synapses. We also hypothesized that as a chaperone, HSP10 might affect aSyn aggregation. We tested both hypotheses and assessed (1) HSP60/ HSP10 folding activity in the presence of different aSyn species and (2) the aggregation of aSyn in the presence of HSP10. We found that aggregated forms of aSyn (PFFs) did not change the folding activity of the already formed HSP10/HSP60 complex per se. However, pre-incubation of PFFs with HSP10, to mimic the interaction between aSyn and HSP10 in the cytosol, reduced the folding activity of the complex by approximately 50%. Because under pathological conditions aSyn accumulates and aggregates in the cytosol, where newly synthetized, non-complexed HSP10 is also present, our data suggest that certain aggregated forms of aSyn interact with HSP10 in the cytosol, prevent its import into mitochondria, and thereby reduce the activity of the HSP60/HSP10 complex. This is supported by the SPR data showing that aSyn monomers and PFFs interact with HSP10 with high affinity. In comparison, the dissociation constants obtained in the SPR experiment were identical to those described for aSyn and S100A9 interaction (Horvath et al., 2018) . In addition, we found a significant fraction of HSP10 in the cytoplasm, alongside decreased levels of mitochondrial HSP10.
We also found that HSP10 influenced the aggregation of aSyn. Although monomeric aSyn aggregated faster in the presence of HSP10, the aggregation was slower when both aSyn PFF and HSP10 were present. These results suggest that aSyn aggregation may start at lower concentrations when HSP10 is present and that once aSyn seeds are formed, the aggregation process is slowed down by HSP10. The aggregation properties of A30P aSyn species were not altered by HSP10. Because the effects of A30P aSyn on mitochondria appeared to be stronger than those observed with WT aSyn, and increasing the levels of HSP10 did not improve aSyn pathology or mitochondrial dysfunction, one might speculate that A30P aSyn oligomeric or monomeric species trap HSP10 and induce pathology. Further investigations in future will be necessary to clarify the significance of these findings.
The connection between aSyn pathology and mitochondrial dysfunction in PD is complex. Dysfunctional mitochondria produce less ATP and more ROS, and because of the high energy demand in the synaptic compartment, lowering ATP leads to synaptic dysfunction (Rangaraju et al. 2014) and triggers aSyn accumulation (Nakata et al., 2012) . In addition, mitochondrial health correlates with axonal transport, regeneration (Smith and Gallo, 2018) , and, consequently, the clearance of aSyn (Oh et al., 2017) . Similarly, increased ROS levels facilitate aSyn aggregation (Tabner et al., 2006; Fernandes et al., 2014) . This suggests that improving mitochondrial health might also contribute to a reduction in the levels of pathological species of aSyn. Other chaperones, such as HSP27 (Outeiro et al., 2006; Cox et al., 2018) , HSP70 (Outeiro et al., 2008; Gao et al., 2015; Aprile et al., 2017) , and HSP90 (Du et al., 2014; Xiong et al., 2015) , have already been shown to modulate aSyn aggregation and toxicity. However, in our model, we found no evidence for aSyn-associated changes in the levels of these chaperones. We found that the levels of HSP10 were reduced upon aSyn overexpression and that overexpressing HSP10 mitigated most mitotoxic effects of WT aSyn but not of A30P aSyn. Importantly, expression of HSP10 in the SN of WT aSyn mice, but not A30P aSyn mice, improved mitochondrial respiration and ROS handling in striatal synapses, consistent with the effects observed in synaptic terminals.
In general, we found that A30P aSyn induced stronger cellular pathologies compared with WTaSyn. Our data suggest that the differences between WT and A30P aSyn might be because of the mutation, rather than a simple protein load effect, because in our cell culture model the levels of human aSyn were identical ( Figure 2B ). The levels were also similar in the two transgenic mouse lines used ( Figure 4A ). A30P mutant aSyn impairs autophagy (Song et al., 2009) , which leads to higher ER stress and, ultimately, mitochondrial dysfunction (Ganguly et al., 2018) , suggesting also a more downstream, non-HSP10-dependent effect. Consistently, we found that overexpression of HSP10 was less efficient in mitigating those pathologies. The molecular effects of the A30P mutation on aSyn function and toxicity are still unclear. Although a recent study suggests that the A30P mutation induces a loss of function (Pozo Devoto et al., 2017) , others support an age-dependent reduction in mitochondrial function (Robson et al., 2018) and increased toxicity (Ysselstein et al., 2017) . We have also recently reported different effects on gene expression in both cell and animal models (Paiva et al., 2018; Pinho et al., 2019) , and different aggregation propensity , suggesting that multiple effects may contribute to the differences observed.
In conclusion, our study provides novel insight into the molecular mechanisms underlying aSyn-mediated mitochondrial dysfunction in PD and other synucleinopathies and opens novel perspectives for the design of strategies aimed at improving cellular pathologies associated with these devastating diseases.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents may be directed to and will be fulfilled by the corresponding author Tiago F. Outeiro (touteir@gwdg.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethical statement and animal lines Animal procedures were performed in accordance with the European Community (Directive 2010/63/EU), institutional and national guidelines (Landesamt f€ ur Verbraucherschutz, Braunschweig, Lower Saxony, Germany, license number: 33.9-42502-04-17/2413). All mice were housed at controlled temperature and 12:12 h light/dark cycle. Number of animals included in the analysis was estimated by power analysis (R software packages, Vienna, Austria), and selection of animals was randomized. Mice that lost more than 20% of the body weight during the treatment were excluded from the experiment. Young (2-3 months old) and middle-age (5-7 months old) wild-type (DBA/2F1 (DBA; control of WTaSyn) or C567BL/6J (Bl6; control of A30PaSyn) and human aSyn-expressing mice (Thy-1 promoter; WT or A30P human aSyn (Kahle et al., 2000; Rockenstein et al., 2002; Szeg} o et al., 2012) ) were used in the study. Only male mice, or female and male mice mixed groups (only for lentivirus injection) were used.
Patients and controls
Human brain samples from patients with PD or DLB, and control individuals were obtained from the Newcastle Brain Tissue Resource (NBTR) or from the Regional Ethical Review Board of Lund University, Sweden (2014/631). Samples were classified according to the disease diagnostics and were anonymized, information about age, sex and post-mortal delay are indicated in Table S2 . The use of human material was approved by the Ethics Committee for Using Human Brain Samples for Fundamental Research, University Medical Center, Gö ttingen.
METHOD DETAILS

Lentivirus injections and tissue dissection
To inject lentivirus, only young (2-4 months old) female and male mice were used. Two times 0.5 ml lentivirus (adjusted to 1x10 7 TU/ml) were injected in the substantia nigra of both hemispheres . One month after the injection, brain tissue was rapidly dissected for mitochondrial assays and protein analysis and processed immediately. For immunofluorescence analysis, brains were fixed in 4% PFA, and after cryoprotection (30% sucrose), 30 mm coronal sections were cut.
Primary neuronal culture Primary neuronal cultures (prepared from E18 Wistar rat embryos, mixed sex) were infected with lentivirus coding GFP, WTaSyn or A30PaSyn on day 4 (MOI 1), and with GFP or HSP10-Flag on day 7 (MOI 1). Cells were maintained in Neurobasal supplemented with B27 and 2mM glutamax (Villar-Piqué et al., 2016; Szeg} o et al., 2017) .
Constructs
Full-length human aSyn cDNA (SNCA, gene association NM000345-WT and A30P mutation) was sub cloned into a 3rd-generation lentiviral vector CD526A-1, followed by a T2A-GFP sequence, under the original vector promoter (EF1a). The inserts (aSyn, WT and A30P mutation) including the Kozak sequence have been generated by PCR. The CD526A-1 vector containing only the T2A-GFP cassette was used for control experiments. The T2A sequence is cleaved after translation, generating two proteins from a single open reading frame and resulting in stoichiometric expression of the gene of interest and the fluorescent reporter (Tang et al., 2009) . Full-length human heat shock protein family E (HSP10) member 1 (HSPE1, gene association NM 0022157.2) was sub cloned into a 3rd-generation lentiviral plasmid with hUbC-driven EGFP, where the original GFP cassette has been replaced by the HSPE1 gene including the Kozak sequence and a C-terminal Flag tag. The FUGW vector containing only the GFP cassette was used for control experiments. 
